Radiolabeled PSMA Inhibitors.
Oliver C NeelsKlaus KopkaChristos LioliosAli Afshar-OromiehPublished in: Cancers (2021)
PSMA has shown to be a promising target for diagnosis and therapy (theranostics) of prostate cancer. We have reviewed developments in the field of radio- and fluorescence-guided surgery and targeted photodynamic therapy as well as multitargeting PSMA inhibitors also addressing albumin, GRPr and integrin α v β 3 . An overview of the regulatory status of PSMA-targeting radiopharmaceuticals in the USA and Europe is also provided. Technical and quality aspects of PSMA-targeting radiopharmaceuticals are described and new emerging radiolabeling strategies are discussed. Furthermore, insights are given into the production, application and potential of alternatives beyond the commonly used radionuclides for radiolabeling PSMA inhibitors. An additional refinement of radiopharmaceuticals is required in order to further improve dose-limiting factors, such as nephrotoxicity and salivary gland uptake during endoradiotherapy. The improvement of patient treatment achieved by the advantageous combination of radionuclide therapy with alternative therapies is also a special focus of this review.
Keyphrases
- pet ct
- pet imaging
- prostate cancer
- photodynamic therapy
- cancer therapy
- positron emission tomography
- minimally invasive
- radical prostatectomy
- case report
- quality improvement
- combination therapy
- drug induced
- human health
- fluorescence imaging
- replacement therapy
- atrial fibrillation
- climate change
- surgical site infection